Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RT-PCR Assay Detects and Differentiates Parainfluenza Viruses

By LabMedica International staff writers
Posted on 21 Apr 2009
A real time-polymerase chain reaction (RT-PCR) assay rapidly detection and differentiates parainfluenza viruses 1, 2, and 3.

Real-time technology offers clear advantages over other molecular diagnostic techniques such as microbeads and microarrays because little hands-on time is required, risk of amplicon contamination is eliminated, equipment cost is relatively low, and inducement concerns (resulting from running a large panel of tests, some of which may not be medically-indicated) are minimized.

The ProParaflu+ assay is an in vitro diagnostic product; it yields an objective answer within 3 hours. More...
It is a product of Prodesse Inc. (Milwaukee, WI, USA), a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. Together with ProFlu+ (for influenza viruses) and Pro hMPV+ (for metapneumovirus) the three respiratory products offer seven detections and share an internal control. This enables clinicians to easily run the most appropriate series of tests for their patients from just a single nucleic acid extraction.

Human parainfluenza viruses are a common cause of respiratory infections, especially in children; it is second only to respiratory syncytial virus as a cause of hospitalization of pediatric patients. Parainfluenza 1 virus is the leading cause of croup in children. Parainfluenza 3 is often associated with bronchiolitis and pneumonia. The elderly and the immunocompromised are also at higher risk for lower respiratory tract infections from parainfluenza viruses. Current methods for detection require subjective interpretation from highly skilled laboratory technicians and can take several days to provide a result.

The Prodesse's products can be used on multiple nucleic acid extraction and RT-PCR platforms. The company has filed a submission with the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) for 510(k) clearance to market its ProParaflu+ assay in the United States.

Related Links:

Prodesse Inc.
U.S. Food and Drug Administration




New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Laboratory Software
ArtelWare
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.